{"id":452,"date":"2001-11-01T12:01:00","date_gmt":"2001-11-01T11:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien"},"modified":"2022-03-17T14:09:58","modified_gmt":"2022-03-17T13:09:58","slug":"clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/clopidogrel-bei-instabiler-angina-pectoris-die-cure-studien","title":{"rendered":"Clopidogrel bei instabiler Angina pectoris. Die CURE-Studien"},"content":{"rendered":"<p>Die Thienopyridinderivate Clopidogrel (Iscover, Plavix) und Ticlopidin (Tiklyd u.a.) werden bislang in Kombination mit Azetylsalizyls\u00e4ure (ASS) zur Thromboseprophylaxe nach koronarer Stentimplantation eingesetzt (s. \u00dcbersicht AMB 1999, 33, 33). Nach der CURE-Studie (Clopidogrel in Unstable angina to prevent Recurrent Events trial: N. Engl. J. Med. 2001, 345, 494) wird sich nun vermutlich die Indikation ausweiten. Ziel [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die Thienopyridinderivate Clopidogrel (Iscover, Plavix) und Ticlopidin (Tiklyd u.a.) werden bislang in Kombination mit Azetylsalizyls\u00e4ure (ASS) zur Thromboseprophylaxe nach koronarer Stentimplantation eingesetzt (s. \u00dcbersicht AMB 1999, 33, 33). Nach der CURE-Studie (Clopidogrel in Unstable angina to prevent Recurrent Events trial: N. Engl. J. Med. 2001, 345, 494) wird sich nun vermutlich die Indikation ausweiten. Ziel [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[495,73,731],"class_list":["post-452","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-angina-pectoris","tag-clopidogrel","tag-cure-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/452","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=452"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/452\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=452"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=452"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=452"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}